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Abstract
Background: The CXCR3 receptor and its three interferon-inducible ligands (CXCL9, CXCL10 and CXCL11) have been
implicated as playing a central role in directing a Th1 inflammatory response. Recent studies strongly support that the
CXCR3 receptor is a very attractive therapeutic target for treating autoimmune diseases, such as rheumatoid arthritis,
multiple sclerosis and psoriasis, and to prevent transplant rejection. We describe here the in vitro and in vivo
pharmacological characterizations of a novel and potent small molecule CXCR3 antagonist, SCH 546738.
Results: In this study, we evaluated in vitro pharmacological properties of SCH 546738 by radioligand receptor binding
and human activated T cell chemotaxis assays. In vivo efficacy of SCH 546738 was determined by mouse collagen-
induced arthritis, rat and mouse experimental autoimmune encephalomyelitis, and rat cardiac transplantation models.
We show that SCH 546738 binds to human CXCR3 with a high affinity of 0.4 nM. In addition, SCH 546738 displaces
radiolabeled CXCL10 and CXCL11 from human CXCR3 with IC50 ranging from 0.8 to 2.2 nM in a non-competitive
manner. SCH 546738 potently and specifically inhibits CXCR3-mediated chemotaxis in human activated T cells with IC90
about 10 nM. SCH 546738 attenuates the disease development in mouse collagen-induced arthritis model. SCH 546738
also significantly reduces disease severity in rat and mouse experimental autoimmune encephalomyelitis models.
Furthermore, SCH 546738 alone achieves dose-dependent prolongation of rat cardiac allograft survival. Most
significantly, SCH 546738 in combination with CsA supports permanent engraftment.
Conclusions: SCH 546738 is a novel, potent and non-competitive small molecule CXCR3 antagonist. It is efficacious
in multiple preclinical disease models. These results demonstrate that therapy with CXCR3 antagonists may serve as
a new strategy for treatment of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis, and to
prevent transplant rejection.
Background
Leukocyte infiltration into inflammatory sites is critical for
the initiation and progression of a variety of inflammatory
disorders and is controlled via the activation and signaling
of specific cell-surface chemoattractant receptors by their
cognate protein ligands, termed chemokines. Chemokines,
which are produced by a number of cell types at sites of
inflammation, mediate the firm adhesion of leukocytes to
activated endothelial cells, their subsequent transmigration
and extravasation into the inflamed tissue, and possibly
several cellular signaling pathways involved in cell activa-
tion and differentiation [1-4].
CXCR3 is a seven-transmembrane G-protein coupled
chemokine receptor which has been demonstrated to
play an important role in a variety of inflammatory and
immunological responses. CXCR3 receptor is predomi-
nantly expressed on activated T helper 1 (Th1) cells. Its
ligands, CXCL10 (IP-10), CXCL9 (MIG) and CXCL11
(I-TAC) are expressed by endothelial cells, epithelial
cells and infiltrating leukocytes following stimulation by
interferon (IFN)-g or Type I IFNs and their expression
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is synergistically enhanced by the key pro-inflammatory
mediator tumor necrosis factor (TNF)-a [5-9].
The importance of CXCR3 in leukocyte recruitment was
first demonstrated in the CXCR3 knockout mouse, where
the rejection of a cardiac allograft was significantly delayed
compared to matched wild type animals, and where treat-
ment of the CXCR3-deficient host with the immunosup-
pressive agent cyclosporine resulted in permanent allograft
engraftment [10]. Transplant rejection is caused by infiltra-
tion, activation and expansion of host leukocytes in the
grafted organ resulting in destruction of the donor tissue.
The marked upregulation of CXCR3 ligand expression and
the predominant expression of CXCR3 on infiltrating T
cells during allograft rejection in human and in animal
models indicate a critical role for CXCR3-dependent T cell
recruitment in transplant rejection [11-13]. Similarly, the
upregulation of CXCR3 ligands and the increased number
of CXCR3+ lymphocytes documented in chronic inflam-
matory diseases such as rheumatoid arthritis (RA) [14-17],
multiple sclerosis (MS) [18,19] and psoriasis [20] indicates
the potential importance of CXCR3-mediated leukocyte
recruitment in the pathology of these conditions, and sug-
gests the potential utility of the selective CXCR3 antagonist
in the treatment and amelioration of these disorders.
To date, many different classes of small molecule CXCR3
antagonists have been discovered [21-30], and it was
reported that CXCR3 antagonism reduced inflammation
and cartilage damage in mouse and rat models of collagen-
induced arthritis (CIA), attenuated atherosclerotic plaque
formation, prolonged allograft survival, and inhibited lung
metastasis [21,28,29,31-34]. In this report, we described the
in vitro and in vivo pharmacological characterizations of a
novel and potent CXCR3 antagonist SCH 546738 (com-
pound 8a) [35]. So far, SCH 546738 is reported to have the
highest affinity of 0.4 nM to human CXCR3 receptor. SCH
546738 inhibits CXCL10 and CXCL11 binding and human
activated T cell chemotaxis with nanomolar potency. In
vivo, SCH 546738 shows significant efficacy in mouse CIA
and rat experimental autoimmune encephalomyelitis
(EAE) model. More importantly, we show that combina-
tion of IFN-b therapy and CXCR3 inhibition has an addi-
tive effect on delaying disease onset and attenuating
disease severity in the mouse EAE model. Furthermore,
SCH 546738 delays graft rejection and in combination with
cyclosporine, permits permanent engraftment in the rat
cardiac allograft transplant model. These results demon-
strate that SCH 546738 may offer a tool to evaluate the full
therapeutic potential of CXCR3 antagonism in chronic
inflammatory disease and preventing allograft rejection.
Methods
Materials
All chemokines were obtained from R & D Systems
(Minneapolis, MN). 125I-hCXCL10 was obtained from
PerkinElmer Life Science (Waltham, MA) and
125I-hCXCL11 from GE Healthcare Life Sciences (Piscat-
away, NJ). 35S radiolabeled SCH 535390 (a sulfonamide
analog of the CXCR3 compound series) was made in
the lab.
Synthesis of SCH 546738
Synthesis of SCH 546738 was accomplished by the
method outlined in Figure 1. The 2-chlorine of commer-
cially available pyrazine 1 was regioselectively displaced
with (S)(+)-2-ethylpiperazine in the presence of Pd-cata-
lyst to afford compound 2. Subsequent reductive amina-
tion of compound 2 with N-Boc-piperidin-4-one in the
presence of Ti(OiPr)4 followed by removal of Boc gave
compound 3. The tricyclic compound 3 was reacted
with 4-chlorobenzyl chloride in the presence of excess
base to provide methyl ester 4, which was converted to
SCH 546738 by heating with ammonia.
CXCR3 expressing cells and membrane preparations
The cDNAs encoding human, mouse and rat CXCR3 were
generated based on the published sequences: human
(NM_001504) [5], mouse (NM_009910) [36], rat (NM_
053415) [37]. The cDNAs for monkey and dog CXCR3
were cloned in the lab. All CXCR3 cDNAs were cloned
into the mammalian expression vector pME18Sneo, a deri-
vative of the SRa expression vector as described previously
[38]. IL-3-dependent mouse pro-B cells Ba/F3 were trans-
fected to express CXCR3 of different species and cell mem-
branes were prepared as described previously [39].
Radioligand binding assays
A scintillation proximity assay was used for radioligand
competition binding assays as described previously [39]
with some modifications. For each assay point, 1 µg of
membrane was preincubated for 1 hr with 300 µg wheat
germ agglutinin (WGA) coated SPA beads (GE Healthcare
Life Sciences) in the binding buffer (50 mM HEPES, 1
mM CaCl2, 5 mM MgCl2, 125 mM NaCl, 0.002% NaN3,
1.0% BSA) at room temperature. The beads were spun
down, resuspended in the binding buffer and transferred
to a 96-well Isoplate (Wallac, Gaithersburg, MD). The
indicated concentrations of 125I-hCXCL10, 125I-hCXCL11
or 35S-SCH 535390 with a series of titrations of SCH
546738 were added to start the reaction. After indicated
reaction times at room temperature, the amount of radio-
activity bound to the SPA beads was determined with a
Wallac 1450 Microbeta counter (Wallac).
Human activated T cell chemotaxis assays
The preparation of human activated T cells was per-
formed as described previously [39]. Human peripheral
blood lymphocytes were prepared by Ficoll-Hypaque
centrifugation, depleted of monocytes, and stimulated
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for 2 days with 1 µg/ml PHA (Murex Diagnostics, Dart-
ford, U.K.) and 100 U/ml IL-2 (Sigma, St. Louis, MO) in
RPMI 1640 supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 µg/ml streptomycin, 100
U/ml penecillin, 1% non-essential amino acids and 2
mM HEPES. Following stimulation, peripheral blood
lymphocytes were cultured in above media containing
5% conditioned media (Sigma) for up to 15 days.
Human activated T cell chemotaxis assays were per-
formed using 96-well ChemoTx® microplates (Neuro
Probe, Inc., Gaithersburg, MD) with a 3 µm filter as per
manufacturers’ instructions. Activated T cells were washed
with RPMI medium twice, and then resuspended in the
medium containing 20% FBS. 1.25 × 105 cells/reaction
were mixed with indicated concentrations of the com-
pound and placed on the filter. The compound and che-
mokines were mixed and placed in the bottom well of the
ChemoTx system. After 2.5 hours incubation at 37°C/5%
CO2, the cells were scraped off and the plate system was
centrifuged for 5 minutes at 1000 RPM. The filter screen
was then removed and the ChemoTx plate was inverted
into a 96 well plate (Microlite + #7571 from Thermo Lab-
systems) with a funnel plate. The plate system was centri-
fuged for 5 minutes at 1000 RPM. The volume in the wells
was brought to 100 μl with assay buffer and the plates
were rested for approximately 15 minutes at room tem-
perature. The number of migrated cells was measured
using the Cell Titer Glo Luminescent Assay from Promega
(Madison, WI) as per vendor’s instructions. Chemotaxis is
expressed as a chemotactic index, which is a ratio versus
the one without chemokines (spontaneous migration).
Mouse collagen-induced arthritis
Murine collagen-induced arthritis (CIA) was established
as previously described [40]. Briefly, 12-week-old male
B10.RIII mice (Jackson Laboratories, Bar Harbor, ME)
were immunized intradermally at five sites with bovine
type II collagen (Elastin Products, Owensville, MO)
emulsified with an equal volume of complete Freund’s
adjuvant (CFA). CFA was comprised of a mixture of
incomplete Freund’s adjuvant (Difco, Detroit, MI) and
heat-killed, freeze-dried Mycobacteria tuberculosis (Min-
istry of Agriculture, Fisheries & Food, Surrey, England).
Each mouse received 300 µg/ml bovine type II collagen
and 0.5 mg/ml complete Freund’s adjuvant. Mice were
boosted intraperitoneally with 100 µg of bovine type II
collagen on day 20. Disease progression was monitored
by a standardized visual scoring system with a scale
from 0 to 12 reflecting the degree of swelling/redness of
each paw (maximal score 3 per paw) and the number of
paws (maximal 4) involved per individual animal.
Histopathological analysis
After euthanasia, front and hind paws of the animals
were dissected and fixed by immersion in 10% phos-
phate-buffered formalin before decalcification. Follow-
ing decalcification with Cal-Rite (Richard Allen
Scientific, Kalamazoo, MI), formalin fixed tissues were
processed and sectioned at 5µm. Paraffin sections were
stained with Hematoxylin and Eosin (H&E). The cri-
teria of histopathological analysis was carried out as
described [41]. The changes in joint structures, includ-
ing cartilage destruction, bone erosion/remodelling and
pannus formation were scored as follows: 0 = Normal,
1 = Minimal, 2 = Mild, 3 = Moderate, 4 = Marked,
5 = Severe. A grade of 5.5 was also added to address
full-thickness cartilage breach. Cellular infiltrates and
inflammation in animal joints were scored as the fol-
lowing: 0 = Normal, 1 = Minimal, 2 = Mild, 3 = Mod-
erate, 4 = Marked.
Figure 1 Synthesis of SCH 546738. Synthesis of SCH 546738 was accomplished by the method outlined with details in Methods section.
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Mouse experimental autoimmune encephalomyelitis
Female C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, ME). For immunization, 150 μg
MOG35-55 peptide prepared by Princeton Biomolecules
(Langhorne, PA, USA) and 300 μg killed Mycobacterium
tuberculosis (Difco, Detroit, MI) were mixed in CFA
(Sigma-Aldrich, St Louis, MO, USA) and injected s.c. in
two 50-μl injections over the flanks on day 1. Also, 200 ng
of pertussis toxin (Sigma-Aldrich, St Louis, MO) was
injected i.v. on days 0 and 2. The compound was adminis-
tered orally twice daily. Dosing with the compound started
at day 0, 24 h prior to MOG35-55 immunization (day 1).
Mice were monitored daily and assessed for clinical signs
of disease in a blinded fashion according to the following
criteria: 0, no signs of disease; 1, tail paralysis; 2, limp tail
and hind limb weakness; 3, hind limb paralysis; 4, hind
limb plus forelimb paralysis; and 5, moribund or dead.
Cumulative clinical scores were calculated by adding daily
scores from the day of immunization until the end of the
experiment. Mean clinical scores at separate days and
mean maximal scores were calculated by adding the scores
of individual mice and dividing with the number of mice
in each group, including mice not developing signs of
EAE. All animals were used in accordance with protocols
and guidelines established by institute’s Animal Care and
Use Committee.
Rat experimental autoimmune encephalomyelitis
Male Lewis rats challenged by injection of 50 µl (30 mg) of
a guinea pig spinal cord homogenate in CFA into one
footpad. The animals were treated starting at day 0 and
oral dosing continued throughout the 3-week disease
course, with varying amounts of SCH 546738 in 0.4%
methylcellulose (MC) p.o. Animals were scored for disease
severity: 0, no clinical signs; 1, flaccid tail; 2, hind limb
weakness; 3, complete hind limb paralysis; 4, complete
hind limb paralysis, forelimb weakness or paralysis; 5,
death.
Statistical analysis
For CIA and EAE models, unpaired t-tests were per-
formed using GraphPad InStat version 5.0.1 for Windows
98, GraphPad Software, San Diego California USA
(http://www.graphpad.com). Statistical significance was
evaluated by comparing the vehicle-treated group with
the experimental group using unpaired t-test. Differences
were considered significant when p values were <0.05.
Cardiac transplantation in rats
Cardiac graft of ACI (RT1a) rats was heterotopically
transplanted into the abdominal cavity of Lewis (RT1l)
recipients employing a microvascular surgical technique
as described [42]. The grafts were monitored daily by
abdominal palpation, and the complete cessation of heart
contraction was defined as graft rejection. SCH 546738
or 0.4% methylcellulose (vehicle) was orally administered
at the indicated dose (0.2 ml) twice a day, starting on the
day before transplantation until the day of graft rejection.
To test whether SCH 546738 enhanced the effect of con-
ventional immunosuppressive reagent, the recipients
were received treatment with subtherapeutic dose of CsA
for one week combined with treatment with SCH
546738. Graft survival was analyzed using the log-rank
test. The parametric data were analyzed by Student t test
(2-tailed) using GraphPad InStat version 5.0.1 for Win-
dows 98, GraphPad Software, San Diego California USA
(http://www.graphpad.com). p < 0.05 was considered sta-
tistically significant.
Results
To identify CXCR3 antagonists, we have generated a
mouse Pro-B cell line Ba/F3 stably expressing a high
level of human CXCR3 receptor. The membranes were
prepared for establishing a sensitive binding assay using
[125I]hCXCL10 based on the scintillation proximity
assay [39]. From high throughput screening of small
molecule compound libraries, several lead compounds
were discovered [43]. Through the optimization of the
lead compound, we have found SCH 546738 (compound
8a) [35] to be a selective and potent CXCR3 antagonist
with a good PK for in vivo studies. Its structure is
shown in Figure 1.
Affinity of SCH 546738 for CXCR3 receptor
The affinity of SCH 546738 binding to human CXCR3
receptor was determined by competition binding analy-
sis using 35S radiolabeled SCH 535390 (a sulfonamide
analog of the CXCR3 compound series with a Kd of 0.6
nM) as a competitive tracer. In multiple experiments,
the affinity constant (Ki) of SCH 546738 binding to
human CXCR3 receptor was determined to be 0.4 nM
(data not shown).
Inhibition of CXCL10 and CXCL11 binding to CXCR3
receptor
Competition of human CXCL10 and CXCL11 binding
to human CXCR3 by SCH 546738 was determined at
various concentrations of [125I]hCXCL10 and [125I]
hCXCL11 around the Kd (50-100 pM) for the receptor.
The IC50 of SCH 546738 is constant (~1 or 2 nM) and
independent of the input concentrations of either [125I]
hCXCL10 (25-500 pM) or [125I]hCXCL11 (12.5-250 pM)
(Figure 2), respectively. These results indicate that SCH
546738 is a non-competitive antagonist of both CXCL10
and CXCL11 binding to CXCR3, suggesting that SCH
546738 binds to CXCR3 receptor at an allosteric site
and change its conformation which prevents the binding
of both CXCL10 and CXCL11.
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It is important to investigate species specificity of SCH
546738 to design in vivo preclinical studies. As shown in
Table 1, SCH 546738 has strong cross-species activities
with IC50 of 1.3 nM, 6.4 nM, 5.9 nM and 4.2 nM in
inhibiting the binding of [125I]hCXCL10 to CXCR3 of
monkey, dog, mouse and rat origin, respectively.
Functional inhibition of CXCR3-mediated chemotaxis
The functional activity of SCH 546738 was investigated by
CXCR3-mediated chemotaxis assays using human acti-
vated T cells. SCH 546738 at fixed concentrations of 1, 10
or 100 nM was evaluated for its ability to inhibit human
activated T cell chemotaxis induced by various concentra-
tions of the three CXCR3 ligands CXCL9, CXCL10 and
CXCL11 and the CCR7 ligand CCL19 (MIP-3b). SCH
546738 at 10 nM inhibited T cell chemotaxis induced by
all three CXCR3 ligands about 90% (Figure 3). In contrast,
SCH 546738 did not affect T cell chemotaxis induced by
the CCR7 ligand CCL19. Furthermore, SCH 546738 inhib-
ited T cell chemotaxis induced by the three CXCR3 ligand
among all tested ligand concentrations in an insurmounta-
ble manner, suggesting that SCH 546738 is a non-compe-
titive antagonist, as has been characterized in the
competition binding analyses (Figure 2). It is critical to
have a nonocompetitive antagonist which will inhibit
binding of multiple endogenous ligands and inhibit its
function (or activation) at any possible high local concen-
tration of the ligand in the disease stage.
Biochemical selectivity and pharmacokinetic properties
SCH 546738 was tested at concentrations of 1-10 μM
against a panel of 49 GPCR binding assays. Most of the
assays were not affected by SCH 546738 (Table 2). These
results indicate that SCH 546738 is a highly selective
antagonist of CXCR3. In addition, SCH 546738 has a
favourable pharmacokinetic profile in rodents. Figure 4
shows the plasma concentrations of SCH 546738 in Lewis
rat and C57BL/6 mouse over 24 hr post-dose. The AUC
(0-24 hr) is 7.7 μM.hr in Lewis rat @ 10 mg/kg (mpk) and
is 12.6 μM.hr in C57BL/6 mouse @ 30 mpk. Therefore,
SCH 546738 is suitable for in vivo preclinical studies.
Figure 2 Effect of concentrations of [125I]hCXCL10 and [125I]hCXCL11 on the IC50 of SCH 546738 binding to human CXCR3 receptor.
The ability of SCH 546738 to compete the binding of [125I]hCXCL10 and [125I]hCXCL11 to human CXCR3 receptor was determined using various
concentrations of [125I]hCXCL10 and [125I]hCXCL11 as described in Methods. After 3 hr reaction, specific counts relative to input counts (B/B0) in
the presence of increasing concentrations of SCH 546738 are plotted. The IC50 for each concentration of [
125I]hCXCL10 and [125I]hCXCL11 are
shown.
Table 1 Effect of SCH 546738 on CXCR3 from various
species
Species Human Monkey Dog Mouse Rat
IC50 (nM)
(CXCL10)
0.8 1.3 6.4 5.9 4.2
Competition binding assays using [125I]hCXCL10 were carried out as described
in Methods with membranes prepared from Ba/F3 cells expressing human,
monkey, dog, mouse and rat CXCR3 receptors.
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Administration of SCH 546738 attenuates disease in
mouse collagen-induced arthritis and protects joint
structure
Collagen-induced arthritis (CIA) was induced in male
B10.RIII mice by immunization with bovine collagen
type II (BC II) which resulted in the development of
poly-arthritis in the paw. Sixteen days later which was 4
days prior to receiving a BC II boost (day -4); mice were
randomized into treatment groups with approximately
10% of the animals in each group having developed at
least one swollen paw. Oral twice daily treatment with
SCH 546738 was initiated at this time (day -4) and con-
tinued through day 9, with a BC II antigen boost on day
0. Figure 5 shows that SCH 546738 attenuated disease
development in a dose-dependent fashion, with signifi-
cant reduction of the disease score evident at 40 mpk
on days 4, 7 and 9, while it protected significantly on
days 7 and 9 at 10 mpk. SCH 546738 administration at
3 mpk had no statistically significant effect on disease
severity.
Paws collected on day 9 from the vehicle and 40 mpk
SCH 546738 groups of two independent experiments
were analyzed by histopathology. Statistical analysis of
the combined histopathology scores demonstrated that
in animals treated with 40 mpk SCH 546738, both leu-
kocyte infiltration into the joint and the structural
damage to the bone and cartilage was significantly atte-
nuated (Figure 6). This data demonstrates that therapeu-
tic treatment with a CXCR3 antagonist significantly
impairs the development of disease in an animal model
of rheumatoid arthritis, and supports the clinical devel-
opment of SCH 546738 in this disease.
Administration of SCH 546738 reduces disease in
experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) is an
animal model for human MS and development of disease
is dependent on T cell infiltration into the CNS. In the
murine model of EAE, SCH 546738 was tested in combi-
nation with interferon-b (IFN-b), a current first-line ther-
apeutic for the amelioration of relapsing-remitting MS.
C57BL/6 mice were primed by intravenous injection of
pertussis toxin on day 0 and day 2. EAE was induced on
day 1 by subcutaneous injection of the myelin peptide
MOG 35-55 emulsified in CFA in the back of primed
mice. Disease progression was monitored by a scoring
system as described in Methods. IFN-b administered at
1700 ng by daily intramuscular injection significantly
Figure 3 Effect of SCH 546738 on human Activated T cell chemotaxis induced by CXCL10, CXCL9, CXCL11 and CCL19. Human
peripheral blood lymphocytes were prepared by Ficoll-Hypaque centrifugation, depleted of monocytes, and stimulated by PHA/IL-2. After 7-9
days of stimulation, activated T cell chemotaxis assay was carried out as described in Methods. The medium containing 20% fetal bovine serum
was used for all dilutions of chemokines and compounds. Various concentrations of each indicated chemokine were added to the bottom wells
in the presence of fixed concentrations of SCH 546738 (1, 10, 100 nM) (added both on the filter with cells and in the bottom wells). Chemotaxis
of each sample is expressed relative to spontaneous response (without chemokines) as chemotactic index.
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delayed disease onset and attenuated disease severity at
peak of disease compared to vehicle treated animals (Fig-
ure 7). Similarly, SCH 546738 at 30 mpk orally twice
daily delayed disease onset and attenuated disease sever-
ity on days 17 and 19 (Figure 7). Combination treatment
with SCH 546738 and IFN-b had a significant additive
effect in delaying disease onset and attenuating disease
severity compared to treatment with either SCH 546738
or IFN-b alone (Figure 7) suggesting that a CXCR3
antagonist may offer substantial ‘add-on’ efficacy onto
existing IFN-b therapy and further delay the occurrence
of relapses in MS patients. In addition, EAE was induced
Table 2 GPCR counterscreens of SCH 546738
Assay Inhibition (%) Assay Inhibition (%)
Adenosine A1 0% @ 4 μM Muscarinic M1 22% @ 4 μM
Adenosine A2A 3% @ 4 μM Muscarinic M2 52% @ 4 μM
Adrenergic a1A 11% @ 2 μM Muscarinic M3 27% @ 4 μM
Adrenergic a1B 25% @ 2 μM Muscarinic M4 30% @ 4 μM
Adrenergic a2A 45% @ 1 μM Muscarinic M5 28% @ 4 μM
Adrenergic a2B -2% @ 2 μM Neurokinin NK1 15% @ 2 μM
Adrenergic a2C 76% @ 1 μM Neurokinin NK2 0% @ 2 μM
CCR1 9% @ 10 μM Neurokinin NK3 0% @ 2 μM
CCR2 9% @ 10 μM Neuropeptide Y (Y1) 4% @ 4 μM
CCR3 17% @ 10 μM Neuropeptide Y (Y2) -9% @ 4 μM
CCR5 10% @ 10 μM Neuropeptide Y (Y4) -2% @ 4 μM
CCR7 0% @ 10 μM Neuropeptide Y (Y5) 12% @ 4 μM
CXCR1 13% @ 10 μM Nociceptin NOP1 -21% @ 4 μM
CXCR2 20% @ 10 μM Delta opiate 12% @ 4 μM
Dopamine D1 6% @ 4 μM Kappa opiate 7% @ 4 μM
Dopamine D2 41% @ 4 μM Mu opiate 22% @ 4 μM
Dopamine D3 18% @ 10 μM Prokineticin PKR1 -1% @ 4 μM
Dopamine D4.2 18% @ 10 μM Prokineticin PKR2 -5% @ 4 μM
Histamine H1 46% @ 2 μM Purinergic P2Y1 16% @ 4 μM
Histamine H3 29% @ 2 μM Purinergic P2Y12 10% @ 4 μM
MCHR1 0% @ 10 μM Serotonergic 5HT1A 20% @ 4 μM
MRGX1 1% @ 4 μM Vasopressin (V1a) 7% @ 4 μM
MRGX2 25% @ 4 μM Vasopressin (V1b) 15% @ 4 μM
Vasopressin (V2) 18% @ 4 μM
Vasopressin (oxytocin) 12% @ 4 μM
VR1N 0% @ 4 μM
SCH 546738 was tested at the indicated concentrations in a variety of GPCR assays according to established protocols.
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Figure 4 Plasma concentration versus time profiles of SCH 546738 in Lewis rat and C57BL/6 mouse. SCH 546738 in 0.4% methylcellulose
was administered orally at 10 mg/kg (mpk) in Lewis rats or 30 mpk in C57BL/6 mice. The plasma concentration of SCH 546738 in the blood was
calculated as the mean of 3 animals (n = 3) at indicated time points post-dose. Their AUC from 0 to 24 hr is also calculated and indicated.
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in Lewis rats by subcutaneous injections of guinea pig
spinal cord emulsified in CFA into one hind paw. SCH
546738 reduced the severity of the disease in a dose-
dependent manner as well (data not shown).
Inhibition of CXCR3 delays graft rejection and in
combination with cyclosporine, permits permanent
engraftment
Published data demonstrated that in the CXCR3 knockout
mouse rejection of cardiac allografts was significantly
delayed [10]. Based on this observation SCH 546738 was
tested at various doses by twice daily oral administration
in a rat cardiac allograft model starting at the day of trans-
plantation. SCH 546738 significantly increased the mean
survival time of the graft at 1 mpk (MST = 11 days) when
compared to the vehicle control (MST = 6 days), and
further delayed graft rejection at a dose of 5 mpk (MST =
14 days) (Figure 8). Cyclosporine is the current gold stan-
dard in organ transplant therapies in human. A cyclospor-
ine dose response was conducted earlier in a rat cardiac
allograft model and 2.5 mpk of cyclosporine is a low and
suboptimal dose (data not shown). Figure 8 shows that
cyclosporine significantly delayed graft rejection in the rat
model at a daily suboptimal dose of 2.5 mpk and per-
mitted the permanent engraftment of approximately 40%
of the grafts (>100 days graft survival). In combination
with 2.5 mpk cyclosporine a suboptimal dose of 5 mpk
SCH 546738 twice daily increased the rate of permanent
engraftment to 100% (Figure 8). These data indicate that
the selective inhibition of CXCR3 would have a beneficial
effect on allograft survival and may offer the possibility of
reducing the dose of cyclosporine used in patients, thereby
limiting the potential for serious side effects.
Discussion
The CXCR3 receptor and its three interferon-inducible
ligands (CXCL9, CXCL10 and CXCL11) have been impli-
cated in several Th1-mediated inflammatory diseases.
Recently, the efficacy of the anti-IP-10 antibody MDX-
1100 reported in a phase 2 clinical trial for RA [44] rein-
forced the crucial role of the CXCL10-CXCR3 axis in this
disease, and the therapeutic potential of small molecule
CXCR3 antagonists [45]. So far, only one of the CXCR3
antagonists, AMG487 (T487), progressed to Phase II clini-
cal trials but has been halted because of lack of efficacy.
Since this may have been due to variability in drug expo-
sure, it is clear that this failure is not a misrepresentation
of CXCR3 as a drug target. In this regard, SCH 546738 is
a small molecule non-competitive CXCR3 antagonist with
much higher affinity than AMG487 and therefore may
have better chance to achieve the in vivo efficacy.
In the mouse CIA model, SCH 546738 is efficacious in
reducing disease development by attenuating leukocyte
infiltration into the joint and the structural damage to
Figure 5 SCH 546738 attenuates disease in mouse collagen-induced arthritis. SCH 546738 in 0.4% methylcellulose was administered orally
twice daily at 3, 10 and 40 mg/kg (mpk). Dosing was initiated 16 days (day -4) postimmunization and continued through day 9. The disease
score was significantly decreased in SCH 546738-treated animals as compared with vehicle-treated animals (* p < 0.05, two-tailed t test) at day 4,
7 and 9.
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the bone and cartilage. It is of interest to note that SCH
546738 demonstrated efficacy even though dosing was
started after the disease process was initiated and when
mice had already started to show signs of paw swelling.
It was reported that T487 reduced inflammation and
cartilage damage in mouse and rat models of CIA [21].
In rat adjuvant arthritis, blockade of CXCR3 by anti-
CXCR3 mAb significantly inhibits T cell infiltration of
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Figure 6 SCH 546738 in mCIA: Histopathological analysis of paws on day 9. Paws collected at day 9 from the vehicle (0.4%
methylcellulose) and 40 mpk SCH 546738 groups of two independent experiments were analyzed by histopathology. (A) compares the
histopathological scores of both groups of tissues. Both leukocyte infiltration into the joint and the structural damage to the bone and cartilage
was significantly attenuated in SCH 546738-treated animals (* p < 0.05; ** p < 0.005, two-tailed t test). Example images of paw tissue sections
collected from both groups of animals are shown in (B) (top, phalanges area; bottom, tarsal area). Massive cellular infiltrates and bone/cartilage
erosions were evident in both tarsal and phalanges areas of the vehicle treated mouse paw (left panels). In contrast, cellular infiltrates were
mainly observed in the phalanges region (right top), and rarely in the tarsal region (right bottom) of SCH546738-treated animals.
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arthritic joints and reduces the severity of arthritis [46].
All these data directly demonstrate an important role of
CXCR3 in the development of arthritis and CXCR3
blockade reduces the disease severity in the arthritis. It
is likely that small molecule CXCR3 antagonists may
achieve the efficacy of the anti-IP-10 antibody MDX-
1100 reported in a phase 2 clinical trial for RA.
The available functional data for the role of CXCR3 and
its ligands in EAE are contradictory. Different investigators
have reported conflicting results when using IP-10-/- mice,
anti-IP-10 antibody, anti-sense RNA and vaccines [47,48].
The recent results from CXCR3-/- mice show that CXCR3
is not required for the recruitment of immune cells to the
CNS in MOG-EAE. The work by Liu et al. [49] showed
exacerbation of EAE disease in CXCR3-/- mice and with
neutralizing anti-CXCR3 Abs. It indicates that the exacer-
bation in the CXCR3-/- mice correlates with enhanced
effector T cell proliferation and reduced peripheral and
CNS expression of IFN-g, but with no impact on leukocyte
migration to CNS. A subsequent study by Muller et al.
[50] showed that CXCR3-/- mice had more severe chronic
disease with increased demyelination and axonal damage,
although the number of CD4+ and CD8+ T cells infiltrat-
ing the CNS were similar in CXCR3-/- and wild type mice.
In contrast to MOG-EAE, CXCR3 appears to promote
the lymphocyte accumulation inside the CNS in some
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Figure 7 Combination of IFN-b therapy and CXCR3 inhibition has an additive effect on delaying disease onset and attenuating
disease severity in the mouse EAE model. IFN-b was administered at 1700 ng by daily intramuscular injection and SCH 546738 was orally
twice daily at 30 mpk. The mouse EAE was conducted as described in Methods. Treatment with either IFN-b or SCH 546738 alone or the
combination significantly delayed disease onset and attenuated disease severity (p < 0.05, two-tailed t test) at day 16, 17 and 19.
Figure 8 SCH 546738 delays graft rejection and in combination with cyclosporine, permits permanent engraftment in the rat cardiac
allograft transplant model. SCH 546738 was administered orally twice daily at 1, 5 and 15 mpk. Cyclosporine was administered daily at 2.5
mpk. In the combination study, 5 mpk SCH 546738 and 2.5 mpk cyclosporine were administered. SCH 546738 significantly increased the mean
survival time of the graft at 1 mpk (MST = 11 days; p < 0.05), 5 mpk (MST = 14 days; p < 0.05) and 15 mpk (MST = 14.9 days; p < 0.05) when
compared with the vehicle control (MST = 6 days). Graft survival was analyzed using the log-rank test.
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virus-induced demyelinating disease models [51]. This
may point to disease-specific functions of CXCR3 and its
ligands, which can vary depending on the nature of the
pathogenic insult. These varied results probably reflect the
complex and perhaps divergent roles for the chemokine
system in the pathogenesis of EAE and virus-induced neu-
roinflammatory diseases. Recently, a nonspecific small
molecule antagonist of CCR5, CCR2 and CXCR3 (TAK-
779) was reported to reduce incidence and severity of EAE
by decreasing migration of inflammatory cells into the
CNS [52]. Our study is the first report that a specific small
molecule CXCR3 antagonist SCH 546738 consistently
inhibits both mouse and rat EAE clinical disease with no
evidence of exacerbation. Furthermore, combination of
IFN-b therapy and CXCR3 inhibition has an additive effect
on delaying disease onset and attenuating disease severity
in the mouse EAE model. At least for small molecule
antagonists including SCH 546738, the beneficial effect of
CXCR3 blockade has been observed in EAE. Maybe stu-
dies using CXCR3-/- mice and neutralizing anti-CXCR3
Abs offer some hints as to other possible function of
CXCR3 receptor and its ligands. Beyond leukocyte recruit-
ment, CXCR3 may modulate T cell IFN-g production, reg-
ulation between Th1 vs. Th17 cells, or control T cells at
the perivascular space in the CNS. It is not unlikely that a
small molecule antagonist, a neutralizing antibody or a
genetic deletion can perturb a receptor’s activity in differ-
ent ways, leading to different conclusion about the pro-
tein’s biological function.
The role of CXCR3 in leukocyte recruitment was first
demonstrated in the CXCR3 knockout mouse in year
2000, where the rejection of a cardiac allograft was signifi-
cantly delayed, and resulted in permanent allograft
engraftment with cyclosporine [10]. In addition, lack of
CXCL10 in the graft led to prolonged allograft survival
[53]. However, two recent studies published in 2008
[54,55] questioned the importance of CXCR3 in allograft
rejection and found moderate to little increase in graft sur-
vival using CXCR3-/- mice or small molecule CXCR3
antagonist MRL-957 and anti-CXCR3 antibody targeting
in human CXCR3 knock-in mice. These two studies con-
clude that CXCR3 is not essential for leukocyte recruit-
ment in the cardiac allograft rejection. In contrast,
Uppaluri et al. [56] demonstrates that a CXCR3 blocking
antibody significantly prolonged both cardiac and islet
allograft survival, and induced long-term graft survival
greater than 100 days when combined with rapamycin. In
2009, one study shows that TAK-779 attenuates cardiac
allograft vasculopathy in part by reducing CCR5+ and
CXCR3+ T lymphocyte subset infiltration into the graft
[57]. The other study by Rosenblum et al. [58] shows that
small molecule CXCR3 antagonist AMG1237845 prolongs
allograft survival; however, it does not inhibit leukocyte
recruitment into the graft. The difference in the
contribution of CXCR3 to mouse allograft rejection
observed in similar models in different laboratories can
not be explained by current data sets and additional
experiments are required to clarify these conflicting
results.
In the rat cardiac allograft transplant model, a small
molecule CXCR3 antagonist TLRK-A was reported to
prolong graft survival, but was active only in combination
with cyclosporine [59]. However, another small molecule
CXCR3 antagonist NIBR2130 did not prolong graft survi-
val [55]. In this study, we demonstrate that SCH 546738
delays graft rejection and in combination with cyclospor-
ine, permits permanent engraftment in the rat cardiac
allograft transplant model.
In summary, our study demonstrates that administration
of SCH 546738 attenuates disease in mouse CIA, rat and
mouse EAE, and rat cardiac allograft rejection. Combina-
tion of IFN-b therapy and SCH 546738 has an additive
effect in the mouse EAE model. Furthermore, in combina-
tion with cyclosporine, SCH 546738 permits permanent
engraftment in the rat cardiac allograft transplant model.
The findings from our study and others indicate that
targeting the CXCR3 receptor by small molecule antago-
nists and antibodies can be a promising approach to RA.
Since the results from CXCR3 inhibition in EAE and allo-
graft rejection remains contradictory, we need to better
understand the roles of the chemokine system operating
in the pathogenesis of EAE and allograft rejection that
truly reflects the molecular mechanism in human diseases
and enhance the chance of success in human clinical trials.
Conclusions
In the present study, we describe the in vitro and in vivo
pharmacological characterizations of a novel and potent
small molecule CXCR3 antagonist, SCH 546738. It binds
to human CXCR3 with an affinity of 0.4 nM, which is the
most potent small molecule CXCR3 antagonist reported
so far. Competition binding studies show that SCH
546738 is able to displace radiolabeled CXCL10 and
CXCL11 from human CXCR3 with high affinity (IC50
ranged from 0.8 to 2.2 nM) in a non-competitive manner.
In addition, SCH 546738 has strong cross-species activity
with IC50 of 1.3 nM, 5.9 nM, 4.2 nM and 6.4 nM for
monkey, mouse, rat and dog CXCR3 receptor, respec-
tively. SCH 546738 potently and specifically inhibits
CXCR3-mediated chemotaxis in human activated T cells
with IC90 about 10 nM. SCH 546738 has a favorable
pharmacokinetic profile in rodents. We utilized multiple
preclinical disease models relevant to human rheumatoid
arthritis, multiple sclerosis, transplantation to assess in
vivo efficacy of SCH 546738. We demonstrate that SCH
546738 attenuates the disease development in mouse col-
lagen-induced arthritis model by decreasing both leuko-
cyte infiltration into the joint and the structural damage
Jenh et al. BMC Immunology 2012, 13:2
http://www.biomedcentral.com/1471-2172/13/2
Page 11 of 14
to the bone and cartilage. SCH 546738 also significantly
reduces disease severity in rat experimental autoimmune
encephalomyelitis model, and in combination with IFN-b
in mouse experimental autoimmune encephalomyelitis
model. Furthermore, SCH 546738 alone achieves dose-
dependent prolongation of rat cardiac allograft survival.
Most significantly, SCH 546738 in combination with
cyclosporine supports permanent engraftment. Taken
together, the results show that therapy with potent small
molecule CXCR3 antagonists may serve as a new strategy
for treatment of autoimmune diseases, including rheuma-
toid arthritis and multiple sclerosis, and to prevent trans-
plant rejection.
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